Patent Application
20160169918
The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Jul. 31, 2014, is named PCT_Seq_Listing.txt and is 12,288 bytes in size.
In embodiments, the invention relates generally to diagnostic and therapeutic agents in pulmonary arterial hypertension.
Pulmonary arterial hypertension (PAH) is associated with increased vascular resistance linked to sustained contraction and enhanced proliferation of pulmonary arterial smooth muscle cells (PASMCs); abnormal tone, remodeling in the pulmonary vasculature and inflammation contribute to the progression of the disease. The maintenance of the normally low vascular resistance, pressure and tone in the pulmonary circulation is dependent on the interaction of circulating and locally produced vasomodulatory regulators, many of which act via receptor-mediated signaling pathways. PAH can occur secondary to a number of diseases, such as connective tissue disease (secondary PAH, SPAH), which can be the result of sporadic or familial genetic mutation, or have an unknown cause. PAH has a poor prognosis and remains difficult to treat because few pulmonary-selective vasodilators are available. Current therapy for PAH includes prostanoids, endothelin antagonists, calcium-channel blockers and phosphodiesterase-5 inhibitors. These drugs are not effective in all patient populations, can be cumbersome to use and mortality rate for PAH is still high.
G protein-coupled receptors (GPCRs) are guanine nucleotide exchange factors for heterotrimeric G-proteins, whose α and βγ subunits dissociate and regulate effectors. Gαs stimulates adenylyl cyclase, and Gαi inhibits adenylyl cyclase. GPCRs are the largest receptor family (˜3% of genome) and are the largest class of and attractive drug targets in disease since they are expressed on the plasma membrane and are tissue specific.
GPR75 is an orphan G protein coupled receptor that has been mapped to chromosome 2p16 (an orphan GPCR is a GPCR whose endogenous ligand has not yet been identified). The GPR75 gene encodes the 540 amino acid protein (approximately 78 kDa), which is highly expressed in human retinal pigment epithelium and in brain sections. The full-length amino acid sequence of GRP75 is represented by SEQ ID NO: 1. Due to its high expression in the retina GPR75 is also termed retinal GPCR. Analysis of GPR75 has revealed, that although variations in this gene does not underlie Doyne's honeycomb retinal dystrophy and Malattia Leventinese phenotypes, it may be a candidate gene for age-related macular degeneration.
It has been proposed that Regulated upon Activation, Normal T-cell Expressed, and Secreted (RANTES) Chemokine Ligand 5 (CCL5) and Neuropeptide Y may be ligands for GPR753. Upon treatment with RANTES, an increase in inositol triphosphate (IP3), and stimulation of Ca2+ mobilization has been seen in HEK293 cells overexpressing GPR75. Treatment of GPR75-HEK293 cells with U73122 (a PLC inhibitor) has been found to block the RANTES-mediated increase in Ca2+ mobilization. These findings suggest that GPR75 may couple to Gαq/11. Sequence-structure based phylogeny predicted that Neuropeptide Y may be a potential ligand for GPR75. Although GPR75 has previously been shown to be highly expressed in the brain and the eye, no published data exists regarding the possible role of GPR75 in PASMCs or in PAH. Levels of RANTES are increased in the lungs of patients with PAH. Neuropeptide Y stimulates proliferation of human PASMCs.
Embodiments provide for novel diagnostic and therapeutic agents for treating PAH. More specifically, using an unbiased approach, a G protein-coupled (GPCR) RT-PCR array (Life Technologies), the invention pertains to GPCRs that are abundantly and uniquely expressed in pulmonary artery smooth muscle cells (PASMCs). Data obtained from the GPCR arrays show that human PASMCs express >135 GPCRs, a substantial number of which (e.g., one quarter) may be orphan GPCRs, i.e., ones without known physiological agonists. As described in embodiments herein, GPCR expression has been found to correlate with function (e.g., of Gs-coupled GPCRs with formation of cAMP, a second messenger generated by the receptors, and with a functional response to receptor activation, inhibition of cellular proliferation), further demonstrating that physiologically relevant GPCRs may be identified using methods disclosed herein.
In certain embodiments, the invention provides that the GPCR arrays using mRNA from PASMC isolated from patients with pulmonary arterial hypertension (PAH) showed that PAH (both IPAH and SPAH) is associated with an increase (>2-fold) in the expression of 41 GPCRs and the most significant increase was in the expression an orphan receptor, namely GPR75. In certain embodiments, the invention provides that the expression of GPR75 is significantly increased in PAH-PASMCs from patients and animal models of PAH, e.g., chronic hypoxic (CH) mouse and rat models and monocrotaline (M) rat models, while GPR75 expression appears to be absent in normal PASMCs. In some embodiments, patients having PAH have higher number of circulating microparticles (MPs), as indicated by higher protein levels, and GPR75 may further be expressed by and detected on the MPs, such that MPs of patients with PAH may have greater expression of MPs and of GPR75.
In some embodiments, the invention provides a non-invasive method for diagnosing PAH by determining an amount circulating microparticles (MPs) or an expression level of GPR75 in a biological sample of a subject, such as a fluid or tissue. An increased level of MPs and/or GPR75 expression in the biological sample of the subject is indicative of PAH. In certain embodiments, the biological sample of the subject may be any bodily fluid including, but not limited to, blood, plasma, or serum; or a bodily tissue including, but is not limited to, lung cells or tissue, or heart cells or tissue.
In certain embodiments, GPR75, a previously unknown cell surface receptor, can be used as a therapeutic target for patients with PAH. Because GPR75 is highly expressed in PAH-PASMCs but not normal PASMCs, certain embodiments provide that GPR75, a cell surface receptor of previously unknown function, is a therapeutic target for patients with PAH. Embodiments also provide for methods of treating PAH by targeting or binding GPR75 with inhibitors, such as specific antibodies, inverse agonists, or antagonists, to treat PAH by inhibiting PASMC proliferation, pulmonary arterial pressure and effects of inflammatory cytokines, such as RANTES. In certain embodiments, monoclonal antibodies targeted to the N-terminal of GPR75 may be used to increase cAMP and/or inhibit intracellular Ca2+ and inhibit DNA synthesis, and thus the proliferation, of PAH-PASMCs. For example, an anti-GPR75 antibody may be used, which may be generated against a conserved sequence in the N-termini of the GPR75 protein by cyclic peptide methodology, which is thought to result in higher titer and more specific antibodies.
In further embodiments, the immunogen used to generate the anti-GPR75 antibody may be the synthetic cyclic peptide (PNATSLHVPHSQEGNSTS (SEQ ID NO: 2)-amide). The full-length amino acid sequence of GPR75 (SEQ ID NO: 1) is available under accession number AAH67475 from the National Institutes of Health. It will be readily appreciated by persons skilled in the art that GPR75 has many immunogenic portions that can be used to routinely generate alternative antibodies. In certain embodiments, the anti-GPR75 antibody is a human monoclonal antibody or a monoclonal antibody that is suitable for humanization.
In certain embodiments, an antagonist or inverse agonist to GPR75 beneficially inhibits PAH-PASMC proliferation and decreases pulmonary artery pressure. In certain embodiments, using any art-accepted animal model of PAH (e.g., a chronic hypoxic (CH) rat and mouse model or monocrotaline-treated rats) or appropriate cells (e.g., HEK or PASMCs), agents that inhibit GPR75, such as antibodies, inverse agonists or antagonists directed to GPR75) can be screened and developed to be used in preventing or reversing remodeling of the pulmonary artery and reducing pulmonary artery pressure. Therefore, provided is a direct therapeutic approach for treating PAH by targeting GPR75, either with an antagonist or, inverse agonist, including the use of antibody against GPR75, alone or in combination with currently approved therapies, to inhibit PASMC proliferation, decrease pulmonary arterial remodeling, and thereby decrease pulmonary arterial pressure in PAH.
In certain embodiments, a method for diagnosing or treating pulmonary arterial hypertension (PAH) in a subject comprises obtaining a biological sample from said subject, and measuring an expression level of GPR75 in the sample of the subject, wherein an increased expression level of GPR75 in the sample of the subject as compared to a reference level of GPR75 in a control sample provides a diagnosis, an indication for treatment of PAH or means to monitor therapy of PAH in the subject. In such embodiments, the biological sample may be selected from the group including blood, plasma, serum, lung cells or tissues, and heart cells or tissues. The cells may be pulmonary arterial smooth muscle cells (PASMCs).
In certain embodiments, a method for diagnosing or treating pulmonary arterial hypertension (PAH) in a subject in need thereof may comprise obtaining a biological sample from said subject, and measuring an amount of circulating microparticles (MPs) in the sample of the subject, wherein an increased amount of MPs as compared to a reference amount of MPs in a control sample provides a diagnosis or an indication for treatment of PAH in the subject. In such embodiments, the measuring of the amount of circulating MPs in the sample of the subject comprises detecting GPR75 that is expressed on said MPs.
Embodiments also relate to a kit for diagnosing pulmonary arterial hypertension (PAH) in a subject in need thereof that comprises: (a) a capture reagent comprising one or more detectors specific for binding to circulating microparticles (MPs) and/or to GPR75 expressed thereon; (b) a detection reagent specifically reactive with the capture reagent; and (c) instructions for using the kit for diagnosing and providing an indication of a treatment of PAH in said subject when an increased amount of the circulating MPs or an expression level of the GPR75 is detected in a bodily sample of the subject bodily sample as compared to a reference amount of circulating MPs or a reference expression level of GPR75 in a control sample.
In certain embodiments, a method for treating PAH comprises: administering to a subject thereof a pharmaceutical composition comprising a therapeutically effective amount of an agent that inhibits GPR75. The agent may be a GPR75 inverse agonist or antagonist that interacts with the GPR75 expressed by pulmonary arterial smooth muscle cells (PASMCs) of the subject so as to inhibit signaling or function, or an mRNA, DNA, or protein expression level, of the GPR75. In some embodiments, the agent may regulate a second message signaling pathway associated with the GPR75. In further embodiments, the agent may be an anti-GPR75 antibody, and the anti-GPR75 antibody may be a human or humanized monoclonal antibody.
In certain embodiments, a method for treating PAH comprises administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of an agent that inhibits circulating microparticles (MPs) or GRP75 expressed thereon. In such embodiments, administration of the agent reduces an amount of circulating MPs that are associated with PAH and/or an expression level of GPR75 expressed on MPs associated with PAH. The agent may be anti-GPR75 antibody, and the anti-GPR75 antibody may be human or humanized.
Embodiments provide for novel diagnostic and therapeutic agents for treating PAH.
In certain embodiments, a method for diagnosing or treating pulmonary arterial hypertension (PAH) in a subject comprises obtaining a biological sample from said subject, and measuring an expression level of GPR75 or GPR113 in the sample of the subject, wherein an increased expression level of GPR75 or GPR113 in the sample of the subject as compared to a reference level of GPR75 or GPR113 in a control sample provides a diagnosis or an indication for treatment of PAH in the subject. In such embodiments, the biological sample may be selected from the group consisting of blood, plasma, serum, lung cells or tissues, and heart cells or tissues. The cells may be pulmonary arterial smooth muscle cells (PASMCs). The step of obtaining a biological sample encompasses a broad range of physical activity, including drawing a bodily fluid or tissue from a patient to manipulating a previously drawn sample from the patient while conducting a diagnostic assay, for example.
In certain embodiments, a method for diagnosing or treating pulmonary arterial hypertension (PAH) in a subject in need thereof may comprise obtaining a biological sample from said subject, and measuring an amount of circulating microparticles (MPs) in the sample of the subject, wherein an increased amount of MPs as compared to a reference amount of MPs in a control sample provides a diagnosis, an indication for treatment of PAH or a means to monitor PAH in the subject. In such embodiments, the measuring of the amount of circulating MPs in the sample of the subject comprises detecting GPR75 that is expressed on said MPs. Measurements/data obtained according to diagnostic methods described herein may be used routinely formulating a range of dosages for use in the subject.
Embodiments also relate to a kit for diagnosing pulmonary arterial hypertension (PAH) in a subject in need thereof that comprises: (a) a capture reagent comprising one or more detectors specific for binding to circulating microparticles (MPs) and/or to GPR75 expressed thereon; (b) a detection reagent specifically reactive with the capture reagent; and (c) instructions for using the kit for diagnosing and providing an indication of a treatment of PAH in said subject when an increased amount of the circulating MPs or an expression level of the GPR75 is detected in a bodily sample of the subject bodily sample as compared to a reference amount of circulating MPs or a reference expression level of GPR75 in a control sample.
Capture and detection of GPR75 can be achieved through a wide variety of detection reagents, including labeled antibodies, protein detection assays and mRNA assays, for example.
In certain embodiments, a method for treating PAH comprises: administering to a subject thereof a pharmaceutical composition comprising a therapeutically effective amount of an agent that inhibits GPR75 or GPR113. The agent may be a GPR75 or GPR113 agonist, inverse agonist or antagonist that interacts with the GPR75 or GPR113 expressed by pulmonary arterial smooth muscle cells (PASMCs) of the subject so as to inhibit signaling or function, or an mRNA, DNA, or protein expression level, of the GPR75 or GPR113. In some embodiments, the agent may regulate second message signaling pathway associated with the GPR75 or GPR113. In further embodiments, the agent may be an anti-GPR75 or anti-GPR113 antibody, and the anti-GPR75 or anti-GPR113 antibody may be a human or humanized monoclonal antibody.
In certain embodiments, a method for treating PAH comprises administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of an agent that inhibits circulating microparticles (MPs) or GRP75 expressed thereon. In such embodiments, administration of the agent reduces an amount of circulating MPs that are associated with PAH and/or an expression level of GPR75 expressed on MPs associated with PAH. The agent may be anti-GPR75 antibody, and the anti-GPR75 antibody may be human or humanized. Effective amounts of the composition are those which have the result of at least improving a condition or symptom of a patient with PAH.
An agent administered according to methods described herein may be conjugated to a therapeutic moiety, such as a cytotoxin, a therapeutic agent, or a radioactive metal ion. The conjugates may be used for modifying a given biological response. The agents described herein may be administered in the form of expressible nucleic acids which encode said agents. For instance, the nucleic acid molecules can be constructed from the known coding sequence of GPR75 or GPR113 for RNA interference (RNAi) or be inserted in to vectors and used as gene therapy vectors. Pharmaceutical preparations of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is embedded.
Pharmaceutical compositions may comprise, in addition to the active agent, a wide variety of well-known excipients, diluents and stabilizers as are routinely used in the art of pharmacology. The pharmaceutical compositions may be included in a container, pack, or dispenser, together with instructions for administration.
In practicing methods of the invention, an “effective amount” of an agent in an amount that is necessary to achieve the desired result at prescribed dosages and for periods of time. A therapeutically active amount of GPR75 or GPR113 will be understood by those skilled in the art as modulated by factors such as, e.g., disease state, age, sex, and weight of the patient, and the ability of peptide to elicit a desired response in the patient.
Data obtained from diagnostic methods according to the invention, or from cell culture assays and animal studies, can be used in formulating a range of dosage for use in human subjects. The dosage may vary depending on the form employed and the route of administration utilized. For any compound used in methods of the present disclosure, the therapeutically effective dose can be estimated initially from cell culture assays.
In embodiments, a therapeutically effective amount of protein or polypeptide (i.e., an effective dosage) may range from about 0.001 to 30 mg/kg body weight. The skilled artisan will appreciate that certain factors may influence the dosage required to effectively treat a subject, including (but not limited to) the severity of the disease, disorder, or condition, previous treatments, the general health and/or age of the subject, and presence of any other diseases. Moreover, treatment of a subject with a therapeutically effective amount of an agent (e.g., a protein, polypeptide, or antibody) may include a single treatment or a series of treatments.
Dosage regimens can be adjusted to provide the optimum therapeutic response. For example, several divided doses can be administered daily or the dose can be proportionally reduced as indicated by the exigencies of the therapeutic situation.
Pulmonary arterial hypertension (PAH) is characterized by increased pulmonary vascular resistance, in part due to increased proliferation of pulmonary artery smooth muscle cells (PASMCs). Since the second messenger 3′5′-cyclic adenosine monophosphate (cAMP) decreases proliferation of PASMCs, G protein-coupled receptors (GPCRs) coupled to Gαs are attractive agents for PAH. In carrying out certain embodiments described herein, TAQMAN human GPCR arrays were used to identify the GPCRs expressed by PASMCs isolated from normal subjects and from patients with PAH. The data revealed that human PASMCs express >135 GPCRs, at least 50 of which regulate cAMP formation. It was therefore found that GPCR expression correlates with function e.g., of Gαs-coupled GPCRs with formation of cAMP and inhibition of cell proliferation (a functional response to receptor activation), thus evidencing that physiologically relevant GPCRs had been identified. Experiments relating to PAH-PASMC with GPCR arrays further revealed that PAH (both idiopathic [IPAH] and secondary PAH [SPAH]) is associated with an increase (>2-fold) in the expression of 41 GPCRs. The greatest increase in GPCR expression was of two orphan receptors, namely GPR113 and GPR75, whose expression was absent in normal PASMC. It was also found the mRNA and protein expressions of GPR113 and GPR75 were increased in animal models of PAH. Importantly, treatment of PAH-PASMC with a GPR75 antibody blunted the increased proliferation of PASMC and increased cellular cAMP levels. Taken together, the data summarized herein demonstrates that the GPCR microarray can identify GPCRs that contribute to the physiology of PASMC and can uncover new drug targets, such as GPR75 for PAH—a disease that requires therapies beyond those currently in use.
The pulmonary circulation is a low resistance, low pressure and highly compliant circulation, which allows for free gas exchange. Deoxygenated blood is pumped from the right ventricle through the pulmonary artery, where oxygen diffuses into blood and is exchanged for carbon dioxide in the hemoglobin of the erythrocytes. The oxygen-rich blood returns to the heart via the pulmonary veins to be pumped ultimately from the left ventricles into the systemic circulation. Normal (systolic/diastolic) pulmonary arterial pressure (PAP) is 24/9 mmHg with a mean arterial pressure of 15 mmHg, much lower than the average systolic/diastolic arterial pressures (120/80 mmHg) in the systemic circulation. Abnormal vasoconstriction, pulmonary vascular remodelling and/or thrombosis in situ can lead to an increase in PAP and the development of pulmonary arterial hypertension (PAH), high blood pressure in the pulmonary circulation.
PAH is characterized by a mean PAP of greater than 25 mmHg at rest.1-2 PAH can occur secondary to a number of diseases (secondary PAH, SPAH), such as (but not limited to) connective tissue disease, chronic obstructive pulmonary disease, that can be the result of a sporadic or familial genetic mutation or can be primary or idiopathic (IPAH), which have an unknown cause.3 The female to male ratio for IPAH is about 2:1, suggesting that women may be predisposed to the disease.4
PAH is associated with increased vascular resistance due to sustained contraction and narrowing of the small pulmonary arteries (PAs): increased proliferation of pulmonary artery smooth muscle cells (PASMC) contributes to remodeling of the PAs. Muscularization of peripheral arteries, medial hypertrophy of muscular arteries (which includes proliferation of fibroblasts and PASMC, endothelial cell swelling, and fragmented elastin), neointima formation (invasion of inflammatory cells), plexiform lesion formation (endothelial channel formation), and loss of small precapillary arteries contributes to the progression of PAH.5 Symptoms of PAH include shortness of breath with exercise, difficulty breathing at rest, dizziness and chest pain due to the excessive strain on the heart. The abnormally high pressure in the PA leads to right ventricular hypertrophy, which can ultimately lead to heart failure.
PAH has a poor prognosis and currently no cure. The goal of treating PAH with drugs is to reduce pressure and resistance in the PAs and to increase cardiac output. Current treatments for PAH include anticoagulants, vasodilators, and heart/lung transplantation.6-8 Vasodilators that are currently used clinically are calcium channel blockers, intravenous prostacyclin, inhaled nitric oxide (NO), endothelin receptor antagonists and cyclic nucleotide phosphodiesterase (PDE) 5 inhibitors and a guanylyl cyclase activator. A major issue with the development of drugs for PAH is their lack of specificity for the pulmonary circulation. Vasodilators in the pulmonary circulation also tend to vasodilate the systemic circulation, leading to systemic hypotension. Discovery of pulmonary-selective targets is thus important in the development of future therapies for PAH.
Cyclic AMP (cAMP)
3′,5′-cyclic adenosine monophosphate (cAMP) is a ubiquitous intracellular second messenger that was discovered by Rall and Sutherland in 1958.9 Cyclic AMP has many effects: reduces inflammation and systemic blood pressure, can be pro-apoptotic in certain cell types (such as immature lymphoid cells) or anti-apoptotic in other cell types (such as epithelial cells), decreases platelet aggregation, inhibits fibrosis, causes bronchodilation, inhibits PASMC proliferation, and vasodilates the PA.10-12 An intracellular concentration of cAMP may be determined by activation of G protein-coupled receptors (GPCRs) that stimulate or inhibit the activity of adenylyl cyclases (and thus, the synthesis of cAMP) and by PDEs, which hydrolyze cAMP. Nine membrane-bound isoforms of mammalian ACs have been characterized, each with their own tissue distribution and regulation; AC6, which is Gαs-coupled, is highly expressed in PASMCs.13,14 Eleven PDEs have been characterized that can hydrolyze cAMP to 5′-AMP, thus reducing its intracellular concentration (
Targeting cAMP in PASMC
As outlined above, cAMP relaxes PA smooth muscle and helps control pulmonary vascular tone.18-20 Increasing cAMP also inhibits PASMC proliferation.21-23 A membrane permeable cAMP analog, 8Br-cAMP, reduced the percentage of cells in the S phase of the cell cycle after serum stimulation, by preventing cell cycle progression from G0/G1.24,25 It has been proposed that cAMP decreases smooth muscle cell proliferation through both PKA and EPAC activation and the inhibition of mitogenic pathways.26-31 Stimulation of PKA results in the phosphorylation of a number of proteins, thereby, regulating cellular processes and gene expression, which can produce vasodilation of the PA smooth muscle. PKA can phosphorylate Raf-1 on serines 43 and 621, thus inhibiting p42/p44 mitogen-activated protein kinase (MAPK) activation.32,33 Inhibition of the phosphoinositide 3-kinase (PI3K) pathway by cAMP may also play a role in attenuating cell proliferation.30
EPAC-1 and EPAC-2 are cAMP-dependent guanine-nucleotide-exchange factors for the small GTPases Rap1 and Rap2, which are important mediators of cAMP signaling. EPACs have been associated with various cellular processes, such as integrin-mediated cell adhesion and cell-cell junction formation.34 In a vascular injury mouse model, EPAC-1 was shown to be up-regulated during neointima formation and to promote vascular smooth muscle migration.35 These data suggest that EPAC-1 regulates vascular remodeling upon vascular injury. EPAC-1 is decreased in PAH-PASMCs.31 Elevation of cAMP in response to β2-adrenergic receptor agonists or prostanoids activates both PKA and EPAC and can induce airway smooth muscle relaxation, inhibit airway smooth muscle proliferation, and modulate cytokine secretion. EPAC induces airway smooth muscle relaxation through inhibition of RhoA and activation of Rac1. EPAC and PKA inhibit airway smooth muscle proliferation and cytokine secretion by signaling to PKB/Akt, p70S6K, ERK1/2, and NF-kB.31
There are multiple ways to increase intracellular levels or the function of cAMP in PASMCs and produce vasodilation and decreased proliferation: (1) activate Gαs-coupled GPCRs, block Gαi-coupled GPCRs, (2) increase expression or activity of ACs, (3) inhibit PDE expression or activity, and/or (4) activate downstream effectors of cAMP (PKA and EPAC) or by altering the expression or activity of proteins regulated by PKA and EPAC (
GPCRs comprise a large protein family of 7 transmembrane receptors, which are guanine nucleotide exchange factors for heterotrimeric G proteins. Activation of these receptors occurs when ligands bind to the extracellular domain of the receptor, altering its conformation and in turn, the activity of membrane-bound heterotrimeric guanine nucleotide (G) proteins: guanosine diphosphate (GDP)-bound Gα subunit and a Gβγ complex. Binding of agonist ligands to GPCRs promotes the exchange of the bound GDP for guanosine triphosphate (GTP) on the Gα-subunit, thus facilitating its dissociation from the receptor and the Gβγ heterodimer. The heterotrimeric G proteins are divided into four classes based on their a subunit: Gαs, Gαi, Gαq/11, and Gα12,13 (
Unbiased approaches have begun to identify GPCR expression in specific tissues. The quantification of RNA transcripts for 353 non-odorant GPCRs in 41 tissues from mice revealed new roles for a number of GPCRs in various tissues.40 Many orphan GPCRs (receptors whose endogenous agonist ligand is not known) and olfactory GPCRs are expressed in tissues, but their function has yet to be determined.41 Limited data are available regarding GPCR expression in individual cell types. Because the GPCR profile of PASMCs has not been identified, key GPCRs that regulate the pulmonary circulation may have been overlooked. Profiling GPCR expression in PASMCs from control, IPAH and SPAH patients thus has the potential to identify GPCRs that may contribute to the pathophysiology of PAH and that could be novel therapeutic targets for this disease.
Objectives of the discovery effort included:
Previously unrecognized GPCRs, in particular ones that regulate cellular cAMP concentration or that are uniquely expressed, may be novel and innovative targets for PAH based on their regulation of muscle tone and proliferation in PAH-PASMCs.
PASMCs (Control, IPAH, and SPAH) were isolated as previously described by Murray et al 2011 and grown in LIFELINE CELL TECHNOLOGY media (containing L-glutamine, recombinant human (rh) Insulin, rh FGF-b, Ascorbic Acid, rh EGF, 1× penicillin and streptomycin, and 10% heat-inactivated fetal bovine serum [FBS]) in a humidified 37° C./5% CO2 incubator. Cell number and viability was determined using 0.4% Trypan blue (Invitrogen; Carlsbad, Calif.), and a Bright-Line Hemacytometer (Reichart; Depew, N.Y.). PASMC were used in experiments when they reached 70% confluency.
Human embryonic kidney (HEK) 293 cells were cultured in CORNING CELLGRO Dulbecco's Modification of Eagle's Medium (DMEM) 1× (containing 4.5 g/L glucose, L-glutamine, and sodium pyruvate) with added 10% heat-inactivated FBS and 1× penicillin and streptomycin in a humidified 37° C./5% CO2 incubator. Cell number and viability was determined using 0.4% Trypan blue (Invitrogen, and a Bright-Line Hemacytometer (Reichart). HEK 293 cells were used in experiments when they reached 70% confluency.
Chronic Hypoxic Mouse Model: C57/BL6 mice (3 months old, male) were placed in a hypobaric chamber (0.5 atm) for 4 weeks. Right ventricular hypertrophy was assessed to determine the development of PAH. It was evaluated as the ratio of the weight of the right ventricle to that of the left ventricle plus the septum (Fulton Index). Control mice had an average value of 0.24 and CH mice had an average value of 0.32. This model is commonly used and approved as a valid model of PAH.42,43 All animals were cared for in compliance with the guiding principles and approved by the UCSD Institutional Animal Care and Use Committee.
Adult Sprague-Dawley rats (250-300 g, male) were placed in a hypobaric chamber (0.5 atm) for 2-4 weeks. Right ventricular hypertrophy was assessed to determine the development of PAH. It was evaluated as the ratio of the weight of the right ventricle to that of the left ventricle plus the septum (Fulton Index). Control rats had an average value of 0.22 and CH rats had an average value of 0.32. This model is commonly used and approved as a valid model of PAH.42,43 All animals were cared for in compliance with the guiding principles and approved by the UCSD Institutional Animal Care and Use Committee.
Adult Sprague-Dawley rats (250-300 g, male) were injected once intraperitoneally with MCT (60 mg/kg) and sacrificed 2 weeks later. Right ventricular hypertrophy was assessed to determine the development of PAH. It was evaluated as the ratio of the weight of the right ventricle to that of the left ventricle plus the septum (Fulton Index). Control rats had an average value of 0.20 and MCT-treated rats had an average value of 0.34. This model is commonly used and approved as a valid model of PAH.42,43 All animals were cared for in compliance with the guiding principles and approved by the UCSD Institutional Animal Care and Use Committee.
PASMCs (0.5-1×106) were transfected with 10 μg of plasmid DNA (e.g., GPR75 Plasmid Vector [using pCMV6-Entry Vector] or Empty Vector Control) using an AMAXA NUCLEOFECTOR device and Program A-033 (AMAXA, Köln, Germany). The cells were then plated into a 6-well plate and incubated in a humidified 37° C./5% CO2 incubator for 24-72 hrs.
Prior to transfection (24 hrs) of HEK 293 cells, the cells were first plated into 6-well plates at 50-70% confluency in DMEM with 10% heat-inactivated FBS (no antibiotics). MIRUS TransIT-LT1 Transfection Reagent (7.5 ul) was combined with 250 μL of Opti-MEM I Reduced-Serum Medium and 2.5 μg plasmid DNA (e.g., GPR75 Plasmid Vector [using pCMV6-Entry Vector] or Empty Vector Control). The solution was incubated at room temperature for 30 min; the TransIT-LT1 Reagent: DNA complexes were then added drop-wise. Cells were incubated in a humidified 37° C./5% CO2 incubator for 24-72 hrs.
2 μL of New England Biolabs Inc. (NEB) Buffer 3 was added with 0.2 μL of Bovine Serum Albumin (BSA, 10 mg/mL), 2 μL of plasmid DNA (0.5 μg/μL-1.5 μg/μL), 1 μL of New England Biolabs Inc. Bgl II (10.00 U/mL) restriction enzyme, and 13.8 μL H2O. The digest was incubated at 37° C. for 2 hrs and then visualized using ˜500 ng of digest on agarose gel electrophoresis to confirm the size of the insert.
Primers for each GPCR were designed using the NCBI Entrez search engine and the Primer3 online primer-designing program (from MIT, Cambridge, Mass.) using standard settings. Multiple primer pairs were chosen for each GPCR (ValueGene, San Diego, Calif.) and stored at a concentration of 200 μM.
mRNA was extracted from 1×106 Control (Ctrl)-, IPAH-, and SPAH-PASMC and/or from isolated mouse/rat lungs using RNeasy (Qiagen) according to the manufacturer's instructions. cDNA was synthesized using Superscipt III Reverse Transcriptase kit (Invitrogen), as per the manufacturer's instructions. Real-time PCR was performed using 8 ng cDNA, 0.5 μM forward and reverse primers, and qPCR Mastermix Plus for Sybr Green I (Eurogentec, San Diego, Calif.) and an Opticon 2 RT-PCR machine (MJ Research, Waltham, Mass.). The RT-PCR program and RT-PCR primers are shown in Tables 1 and 2, respectively. Primer efficiency was calculated for each primer set before use. Samples were compared using the relative cycle threshold (Ct) method, normalizing to 28S or 18S rRNA.
GPCR expression was determined using a TAQMAN GPCR array (Life Technologies), according to manufacturer's instructions, with cDNA pooled from Control (Ctrl)- (n=3), IPAH- (n=3), and SPAH-PASMCs (n=3) and the TAQMAN Universal PCR Master Mix. GPCR expression was normalized to that of 18S rRNA.
cAMP Radioimmunoassay
Control-PASMCs, PAH-PASMCs or HEK 293 cells were seeded at 30,000 cells/well in a 24-well plate. After 24 hrs the cells were serum starved for 2 hrs and incubated in the absence or presence of 3-isobutyl-1-methylxanthine (IBMX, 200 μM), a competitive non-selective PDE inhibitor, for 30 min at 37° C. GPCR agonists of interest were then added to the cells with/without forskolin (FSK, 1 μM, a direct activator of AC, which enhances Gαs-GPCR promoted cAMP formation and helps demonstrate Gαi-GPCR activation) for 10 min at 37° C. 10 uM FSK (alone) was used as a positive control. After the incubations, the media was aspirated and 150 μL of 7.5% trichloroacetic acid (TCA) was added to each well.
In studies of conditioned media from hybridomas, control- and IPAH-PASMCs were seeded at 30,000 cells/well in a 24-well plate (˜30,000 cells/well) in Vasculife Smooth Muscle cell media (Life Technologies) and cultured at 37° C., in a humidified 5% CO2 incubator. After 24 hr, the cells were serum-starved for 4 hr, antibody (1 μg/mL ascites, 1 μg/mL mouse IgG or (1:100 conditioned media from hybridoma cultures) was added for 2 hrs, and then 200 μM IBMX was added 30 min prior to addition of 10 μM forskolin for 10 min and then samples were assayed for cAMP.
Assay tubes were filled with 1 mL of 10 mM sodium acetate buffer (pH 4.75) and a standard curve was constructed by serial dilution of stock 5 μM cAMP (Millipore, Billerica, Mass.). An appropriate amount of sample was added to the assay tubes and the samples were acetylated by addition of 20 μL triethylamine (Sigma) and 10 μl acetic anhydride (Sigma). 100 μL of the sodium acetate buffer was added to each well of a 96-well filter plate to prepare the plate and then was removed by vacuum. 50 μL of diluted, acetylated sample was added to each well along with 25 μL diluted antibody [1:1000, 6 μL primary cAMP antibody (Millipore) in 6 mL γ-globulin buffer (100 mg human γ-globulin/100 mL 50 mM NaAc pH 4.75)] and 25 μL diluted 125I radioactivity [16 acetylated adenosine 3′,5′-cyclic phosphoric acid, 2′-O-succinyl [125I]-iodotyrosine methyl ester (PerkinElmer) in 3 mL γ-globulin buffer so that 0.001 mCi of 125I could be added to each sample. The 96-well filter plate containing the sample was incubated overnight at 4° C.
Following overnight incubation, 50 μL secondary antibody (BIOMAG Goat anti-Rabbit IgG 8-4300D, Qiagen) was added to each well and the plate was incubated for 1 hr at 4° C. The wells were then washed with 100 μL of 12% polyethylene glycol in 10 mM sodium acetate (pH 6.2) three times. The base of the plate was then removed with a MultiScreen Punch Kit (Millipore) into fresh assay tubes and then counted on the WIZARD2 Automatic Gamma Counter (PerkinElmer).
Ctrl- and PAH-PASMCs or HEK 293 cells were seeded at 30,000 cells/well on a 6-well plate (Greiner Bio-One, Monroe, N.C.) for 24 hr and then serum-starved for a further 24 hrs. GPCR agonists/antagonists/GPR75 antibody in the absence or presence of 200 μM IBMX and [3H] thymidine (1 μCi/ml) were added to the cells for 24-48 hr. Following incubation, cells were washed with a large volume of cold phosphate buffer saline (PBS) and then twice with a large volume of cold 7.5% TCA. The precipitated material was dissolved with 0.5 M NaOH and combined with 3 mL of scintillation fluid (Ecoscint O, National Diagnostics) and radioactivity was determined using a liquid scintillation counter (Beckman Coulter LS 1801).
Cells were washed with cold PBS on ice and lysed in 80 μL-150 μL of lysis buffer (Novagen Cytobuster protein extraction reagent). Protein concentration was determined using a Bio-Rad Protein Assay Dye Reagent according to the manufacturer's instructions.
Lungs and hearts were isolated from control and PAH animals and 10 mg of tissue was homogenized using a glass homogenizer in 400 μL of 1× lysis buffer (Cell Biolabs, Inc.). Samples were then centrifuged at 1200 rpm for 10 min at 4° C. and the supernatant was collected. Protein concentration was determined using a Bio-Rad Protein Assay Dye Reagent Concentrate, according to the manufacturer's instructions.
7.5 μl of NUPAGE LDS Sample Buffer 4× (Invitrogen), 0.75 μl of reducing agent (2-mercaptoethanol for electrophoresis >=98%, Sigma), and an appropriate amount of lysis buffer were added to purified protein samples (to give a final protein concentration of 1-5 μg protein/20 mL). Samples were loaded onto pre-cast 4-12% gel (Invitrogen) and run for 1 hr at 200V, 40 mA, and 25W. Gels were incubated in 10% methanol transfer buffer for 10 min and protein was transferred to polyvinylidene fluoride (PVDF) membrane using the iBlot (Invitrogen). Membranes were then blocked in 5% milk or BSA (in PBS Tween [PBST], dependent upon antibody) for 1 hr. Primary antibody [1:1000 dilution in 1% milk/BSA] was then added and the membrane was incubated overnight. The following day, it was washed 3 times (10 min/wash) with PBST at RT. Secondary anti-rabbit or anti-mouse antibody (1:5000 or 1:3000 respectively in 1% milk/BSA, AbCam) was added and incubated for 1 hr. The membranes were washed 3 additional times (10 min/wash) with PBST at RT and ECL luminescence (GE Healthcare) was added for detection.
Ctrl- and PAH-PASMCs were grown on sterile 12 mm coverslips pre-coated with poly-D-lysine. Cells were washed twice with PBS at 37° C., then 1 mL of fixative (2% paraformaldehyde) was added for 10 min. Aldehyde groups were then quenched by incubation with 100 mM glycine (in PBS, pH 7.4) for 10 min. Cells were washed twice with PBS and then with blocking buffer (1% BSA/PBS/0.05% Tween) for 30 min at room temperature and then with primary antibody in that buffer and incubated (1:250) overnight at 4° C. Cells were then washed 3 times with wash medium (PBS/0.1% Tween20) for 5 min each at room temperature. Blocking buffer was then added containing secondary antibodies (1:250) for 60 min at room temperature. Cells were washed 6 times for 5 min each in wash medium at room temperature and then incubated with 4′,6-diamidino-2-phenylindole (DAPI, 1:5000) for 20 min in the dark and, mounted on slides with 10 μL of gelvatol. Slides were left to dry overnight at 4° C. Images were acquired using a confocal microscope.
Lungs from Control and Chronic Hypoxic rats were cut into semi-thin sections (10 microns). Sections were fixed in cold acetone, blocked with 4% BSA in 0.1% Tween and PBS, and incubated with primary antibodies (1:100) in 4% BSA in 0.1% Tween and PBS, and incubated with Alexa-conjugated secondary antibody (1:250). Samples were mounted in gelvatol. Specificity of staining was determined by omission of the primary antibody. Images were obtained using a laser scanning confocal microscope.
1-20 μg of lysate was combined with 1 μL of 10× Glycoprotein Denaturing Buffer (NEW ENGLAND BIOLABS Inc.) and H2O in 10 μL total volume. The sample was denatured by heating at 100° C. for 10 min. The reaction volume was increased to 20 μL by adding 2 μL of 10×G7 Reaction Buffer, 2 μL of 10% NP-40, H2O and 1-2 μL PNGase F (500,000 U/mL, NEW ENGLAND BIOLABS Inc.) and then incubated at 37° C. for 1 hr.
Platelet-poor plasma (PPP) was prepared from patients. Platelets were removed from plasma by centrifugal force: first at 1500×g for 25 min, then by a second centrifugation at 15,000×g for 45 min. The PPP (supernatant) was removed, placed into ultracentrifuge tubes and topped off with phosphate buffer saline (PBS) and then centrifuged at 100,000×g for 75 min at room temperature. All but 100 μl of supernatant/pellet at the bottom of the tube (microparticle-enriched fraction) was removed for protein and western blot analysis.
Hybridoma clones were grown in DMEM/F12 media, supplemented with L-glutamine, HEPES, 10% heat inactivated Fetal Bovine Serum (FBS) and penicillin/streptomycin. Each hybridoma line was expanded in a 225 cm2 vented cap flask in a volume of 50 mL. Hybridoma cells were grown for ˜2 weeks. Cells were removed from media via centrifugation once at 233×g and then at 931×g). Supernatants were used at a 1:100 dilution in cAMP accumulation assays.
Values are expressed as mean±SEM. Statistical significance was determined via an unpaired or paired Student's test or an Anova when applicable. A value of P<0.05 was considered statistically significant.
Using an unbiased approach, a TAQMAN GPCR array, GPCR expression in Ctrl-, IPAH-, and SPAH-PASMCs was identified. This approach was used to identify GPCRs that are higher or uniquely expressed in patients with PAH among the 384 genes that were analyzed (29 housekeeping genes+355 non-chemosensory GPCRs). Results showed that that Ctrl-PASMCs (n=3) express 135 GPCRs (including 56 orphan receptors), IPAH-PASMCs (n=3) express 115 GPCRs (51 orphan receptors) and SPAH-PASMC (n=3) express 81 GPCRs (32 orphan receptors) (Table 3). The non-orphan expressed GPCRs in each cell type were classified further and separated according to their linkage to specific G proteins (Gαs/Gαi/Gαq/11/Gα12/13, Table 4) by using the 2011 BJP (British Journal of Pharmacology) Guide to Receptors and Channels and the IUPHAR Database of Receptors and Ion Channels as references. The results for the three highest expressed Gαs-, Gαi-, Gα12/13-linked GPCRs from Ctrl-, IPAH-, and SPAH-PASMCs are shown in Tables 5-8. The values are shown as ΔCt, whereby the cycle threshold (CO for each GPCR RNA is normalized to that of 18S rRNA; a lower Ct value thus indicates higher expression. Categorizing the receptor expression in each group allowed for the determination of the expression of GPCRs that regulate cAMP and highlighted potential therapeutic targets, since increases in cAMP accumulation decrease proliferation and vasodilate PASMC.18-20,26-31
The highest expressed GPCRs, determined by the TAQMAN GPCR array, were confirmed by real-time PCR to ensure validity of the array data. The results confirmed the expression of the 3 highest expressed Gαs-, Gαi-, and Gαq/11-coupled GPCRs and orphan receptors in Ctrl-PASMCs (Table 9). Data from the individual real-time PCR studies generally correlated well with values from the microarray. The overall r2 value was calculated to be 0.70 (
To further validate the TAQMAN GPCR array, functional studies on the Gαs-coupled GPCRs that were expressed at high, intermediate and low levels in Ctrl-PASMCs were performed in order to determine if agonist-induced cAMP accumulation of these GPCRs correlated with their mRNA expression. The highest, intermediate and lowest Gαs-coupled GPCRs tested were the adenosine 2B receptor (A2BR, ΔCt=18), the vasoactive intestinal peptide receptor (VIPR1, ΔCt=19), the prostacyclin receptor (IPR, ΔCt=20), the prostaglandin E2 receptor (EP2R, ΔCt=22) and the gastric inhibitory polypeptide receptor (IPR, ΔCt=20). cAMP accumulation (fmol cAMP/cell/10 min treatment with agonist) in response to receptor agonists, CV1808 (A2BR, 1 μM:0.6 fmol), VIP (VIPR1, 1 μM: 0.2 fmol), epoprostenol (IPR, 10 μM: 0.4 fmol), butaprost (EP2R, 1 μM: 0.4 fmol) and GIP (GIPR, 1 μM: 0.2 fmol) correlated with receptor mRNA expression (r2=0.31,
The ability of the agonists was tested and the results are shown (in
Also evaluated were cAMP formation and anti-proliferative response mediated by the Vasoactive Intestinal Peptide (VIP), the second highest expressed Gαs-coupled GPCR in Ctrl-PASMCs (Table 9). As shown in
Investigations were conducted regarding expression and function of the oxytocin receptor, the second highest expressed Gαi-coupled GPCR in PASMCs (Table 9). It was found that the oxytocin receptor is expressed on the membrane of Ctrl-PASMCs and that its agonist oxytocin decreased cAMP levels and increased proliferation of PASMCs (
The altered expression of GPCRs in PAH-PASMCs could provide insight into the possible mechanisms that contribute to the development and progression of the disease as well as defining possible targets for future therapy. Using the data derived from the TAQMAN GPCR array, we sought to identify GPCRs that showed the greatest differences in expression between Ctrl- and PAH-PASMCs or GPCRs that were expressed in one cell type but not another (uniquely expressed GPCRs). GPCR expression was compared between Ctrl- and PAH-PASMCs (both obtained from patients with idiopathic and secondary PAH).
Tables 10-13 show the 3 GPCRs that have the greatest increase or decrease in expression in IPAH-/SPAH-PASMCs compared to Ctrl-PASMCs. These GPCRs could be novel therapeutic targets due to their altered expression in the diseased cells.
Multiple GPCRs that are uniquely expressed in PAH-PASMCs compared to Ctrl-PASMC: 26 GPCRs were uniquely expressed in either IPAH or SPAH-PASMCs compared to control cells. Of these 26 GPCRs, only 2 were expressed in both IPAH- and SPAH-PASMCs: GPR75 and GPR113, both of which are orphan receptors (Tables 14 and 15). IPAH was associated with a much greater number of uniquely expressed GPCRs than was SPAH.
Expression of GPR113 in PASMC from PAH Patients and Animals with Experimental PAH
Protein expression of GPR113, one of the orphan GPCRs whose mRNA was uniquely expressed in PAH-PASMCs, was assessed in Ctrl- and PAH-PASMCs cells (
GPR75 Has Increased mRNA and Protein Expression in PAH
GPR75 is the other GPCR whose mRNA is uniquely expressed in both IPAH- and SPAH-PASMCs. Consistent with this result, in PASMC from each SPAH-patient there was at least an 8-fold increase in protein expression of GPR75 compared to control and in PASMC from each IPAH-patient there was at least a 15-fold increase compared to control (
To visualize GPR75 expression, immunofluorescence using a GPR75 N-terminal binding antibody (without permeabilizing the cells) was performed.
To determine if the increase in GPR75 expression with PAH-PASMC also occurs in animal models of PAH, GPR75 expression was evaluated in lungs from CH mice, CH rats, and MCT-treated rats.
GPR75 is an orphan receptor whose endogenous ligand is currently unknown and about which little information is available. Because its mRNA and protein expression is increased in PAH-PASMC and in the lungs of PAH animal models compared to control. An antibody that has been generated against the N-terminal of the receptor (accessible from outside the cell) was tested to determine if it might “block” the receptor. The antibody was obtained and is commercially available from FabGennix Inc. International (Catalog No. GPCR75-101AP). It was reasoned that this antibody, but not an antibody directed at cytoplasm-exposed domains, e.g., intracellular loops or the C-terminal, might block GPR75. Immunoglobulin (IgG) was used as a control. cAMP accumulation and proliferation in PASMCs was then evaluated to determine the role of GPR75 in the function of PAH-PASMCs.
The antibody was added at 1 μg/mL for 2 hrs prior to 10 min stimulation with forskolin (FSK). The N-terminal GPR75 antibody did not significantly alter FSK-induced cAMP accumulation in Ctrl-PASMC compared to the IgG-control (
After obtaining the results in
In order to further investigate the function of GPR75, the receptor was overexpressed in heterologous cells so as to mimic its increased expression in IPAH-PASMCs. Primary cells, such as PASMCs, are difficult to transfect due to their membrane integrity; therefore initial experiments were performed in Human Embryonic Kidney (HEK) 293 cells. HEK 293 cells were transfected with a pCMV6-Entry Vector (4.9 kb) alone or vector with a GPR75 insert (1.6 kb); the plasmid is shown in
HEK cells engineered to overexpress GPR75 (72 hrs-transfected cells) had significantly lower cAMP levels compared to cells transfected with the empty vector control (
GPR75 overexpressed HEK 293 cells also show a significant increase in proliferation compared to empty vector-transfected cells (
GPR75-expressing HEK 293 cells also have increased DNA synthesis compared to empty vector-transfected cells (
PASMCs were transfected using electroporation with an Amaxa nucleofector device to express GPR75 (
Detection of GPR75 by Western Blot often revealed, double or triple bands (
A deglycosylation assay was performed to demonstrate that GPR75 is glycosylated and to investigate if its migration pattern changed.
These data suggest that GPR75 is glycosylated. Interestingly the GPR75 receptor seems to change in glycosylation state in PAH, as shown for IPAH-PASMC and CH rat hearts (
Circulating Microparticles in Humans and its Expression is Increased in Microparticles from Patients with PAH
In embodiments, microparticles can be isolated from the peripheral blood by centrifugation of plasma. PAH (PAH) subjects have higher circulating microparticle protein levels (
PAH is characterized by increased pulmonary vascular resistance, in part due to enhanced vasoconstriction and increased proliferation of PASMCs. Finding unique GPCRs in PAH-PASMCs through expression profiling that compares normal and diseased patient-derived cells could be useful for uncovering new targets for PAH in the disease. Unbiased approaches have begun to identify GPCR expression in specific tissues. The quantification of RNA transcripts for 353 non-odorant GPCRs in 41 tissues from mice revealed new roles for a number of GPCRs in various tissues.40 Many orphan GPCRs (receptors whose endogenous agonist ligand is not known) and olfactory GPCRs are expressed in tissues, but their function has yet to be determined.41 Limited data are available regarding GPCR expression in individual cells, which can express >100 GPCRs.44 Because the GPCR profile of PASMC has not been identified, key GPCRs that regulate pulmonary circulation may have been overlooked.
Microarray data, such as those by Affymetrix, that assess total cellular mRNA are not optimal for detecting the expression of GPCRs. A specific TAQMAN GPCR array was therefore used to investigate GPCR expression in control- SPAH- and IPAH-PASMC. Microarrays are one of the leading methods to identify differentially expressed genes, however their reliability in detecting differences in RNA expression hinges on many factors. These factors include RNA extraction, probe labeling, hybridization conditions, as well as array production. Due to such limitations in reliability, mRNAs identified as differentially expressed on the gene array need to be validated with other methods.45 Results obtained from the GPCR array were validated by independent real-time PCR to confirm the relative expression of GPCRs identified from the array and to focus future studies. Real-time PCR is quantitative, requires a low amount of RNA, is relatively inexpensive, and provides rapid results.45,46 Data showed that the GPCR array, with data confirmed by independent real-time PCR (using primers designed in the lab), provides a reliable tool (based on Ct values) to determine GPCR expression in cells (Table 9).
Since mRNA expression may not correlate with protein expression or function, the approaches described herein sought to identify GPCRs that are functional in PASMC. It was found, as a result of use of these approaches, that receptor expression correlates with cAMP production and function (e.g., increases in cAMP accumulation and DNA synthesis, a measure of cell proliferation). The findings of the vasoactive intestinal peptide receptor 1 (VIPR1, Gαs-coupled) and the oxytocin receptor (Gαi-coupled) being highly expressed in PASMCs establish their role in PASMCs. The data show that in PASMC_VIPR1 protein is expressed in the membrane fraction of PASMCs and that its activation by VIP increases cAMP accumulation and decreases their proliferation by roughly 50% (0.1 nM-10 μM VIP,
Expression and function of VIPR1 in PASMC is consistent with recent findings indicating that VIP could be important in pulmonary artery remodeling and even beneficial in the treatment of PAH. VIP (−/−) mice spontaneously develop moderate pulmonary remodeling, variants in the VIP gene occur in IPAH and chronic inhalation of VIP was shown to improve the hemodynamics and exercise capacity in a small (n=8) cohort of PAH-patients.47-49 The expression and function of oxytocin receptors in PASMCs corresponds to previous studies that found oxytocin (0.2 units/kg) increases mean PAP and pulmonary vascular resistance (PVR). Interestingly cytokines, such as IL-6, which are up-regulated in PAH increase the expression of the oxytocin receptor.50 Thus, the data summarized herein validates the use of a GPCR-array as an initial approach to discover highly expressed or unrecognized GPCRs in PASMCs that may contribute to the physiology and pathophysiology of the pulmonary vasculature.
The GPCR microanay, in addition to profiling GPCR expression in a specific cell type, identified uniquely expressed receptors in PAH-PASMCs as potential therapeutic targets for PAH. Orphan receptors can be difficult to study as no agonists or antagonists are available for functional studies. Methods to investigate their signaling and functional role include RNA knockdown, generation of receptor-knockout mice and is of antibodies that can bind receptors and block function (or promote their loss from the cell surface).
Two orphan GPCRs were identified that are uniquely expressed in both IPAH-PASMCs and SPAH-PASMCs compared to control, namely GPR113 and GPR75. Both might be therapeutic targets for PAH. As orphan receptors, GPR113 and GPR75 lack an identified endogenous agonist. Limited research has been done on GPR113: only 5 articles have been published regarding this receptor. The gene for GPR113 maps to chromosome 2p23.3 and makes up a rather large 1,079 amino acid protein (116,341 Da). GPR113 is an adhesion GPCR belonging to family 2B, a family characterized by receptors having long N-terminal extracellular domains. Its expression was thought to be restricted to a subset of taste receptor cells.51,52 It has a GPCR proteolytic site (GPS) domain in its N-terminus and long Ser/Thr-rich regions forming mucin-like stalks. GPR113 has a hormone binding domain and one epidermal growth factor (EGF) domain.53 No commercially available antibodies that were tested allowed assessment of the function of GPR113. In past studies, GPR113 was found to be up-regulated >5-fold in small bowel neuroendocrine tumors compared to normal tissues and thus, perhaps it may be associated with other disease states.54
This application describes the discovery that PAH is associated with increased expression of GPR75. To date only 4 articles have been published regarding GPR75. The gene for GPR75 maps to chromosome 2p16 and encodes a 540 amino acid protein (59,359 Da).55 GPR75 is highly expressed in the retina and central nervous system.56 It has been proposed that Regulated upon Activation, Normal T-cell Expressed, and Secreted (RANTES, Chemokine Ligand 5 [CCL5]) may be a ligand for GPR75. Upon treatment with RANTES, an increase in inositol trisphosphate (IP3), and stimulation of Ca2+ mobilization was noted and treatment with U73122 (a PLC inhibitor) blocked Ca2+ mobilization, suggesting that GPR75 couples to Gαq/11.57 RANTES is a chemokine that recruits leukocytes into inflammatory sites and also induces the proliferation and activation of natural-killer cells. RANTES levels are increased in patients with severe PAH59. Sequence-structure based phylogeny predicted that Neruopeptide Y may be a potential ligand for GPR7560. Neuropeptide Y stimulates proliferation of human PASMCs61.
PAH-PASMCs are known to produce lower basal levels of cAMP than do Ctrl-PASMCs, but the effect of GPR75 and assess its effect on cAMP accumulation in both Ctrl- and IPAH-PASMCs has not been evaluated.11 A commercially available N-terminal antibody was used as a type of antagonist to “block” receptor activation. Antibodies that target intracellular domains with intact cells cannot be used for this purpose as they would need to get into the cell to be functional. An N-terminal GPR75 antibody was found to increase cAMP accumulation and decrease proliferation of PAH-PASMCs, but not control-PASMCs that have lower expression of GPR75. The results suggest that GPR75 is a Gαi-coupled GPCR, in addition to being previously shown as a Gαq/11-coupled.58 A program, PRED-COUPLE2, is a tool that uses amino acid sequence of a GPCR to predict its coupling to G proteins by using a refined library of highly-discriminative Hidden Markov Models. Hits from individual profiles are combined by a feed-forward artificial neural network to produce the final output. Query of the GPR75 sequence predicted its G protein-coupling specificity as follows (on a 1.00 scale): Gαi=0.99, Gαq=0.28, Gαl2/13=0.11 and Gαs=0.02, which is consistent with the experimental results that indicate coupling of GPR75 to Gαi.
HEK293 cells engineered to express GPR75 recapitulate the signaling and functional responses of PAH-PASMCs: decrease in cAMP accumulation and inhibition of DNA synthesis. Such HEK293 cells are potentially useful to screen and identify GPR75-interacting drugs and antibodies as an assay system with functional readouts for discovery and validation of therapeutics for PAH that target GPR75.
Treatment with the N-terminal directed antibody receptor increases cAMP levels (
The initial studies here used an N-terminal directed polyclonal antibody to study PAH-PASMCs and GPR75-expressing HEK 293 and indicated that this “blocking” antibody can restore the phenotype of PAH-PASMCs to that of PASMCs from control subjects, in terms of cAMP accumulation and DNA synthesis. To develop a more therapeutically relevant approach, monoclonal antibodies (mAbs) were generated. The use of mAbs is more advantageous than polyclonal sera because mAbs bind to their targets with high specificity, have less cross-reactivity with other proteins, and therefore have excellent potential and established utility as therapeutic agents. Custom monoclonal antibodies were generated with specificity to a particular epitope (amino acid sequence: PNATSLHVPHSQEGNSTS (SEQ ID NO:2)-NH2) in the N-terminal (extracellular) domain of the GPR75 protein. Antibodies were generated in mice. Tests of the ascites fluid from seven mice yielded 3 that recognized GPR75 on western blots. Those 3 hybridomas were cultured and their conditioned media tested for ability to raise cAMP in PAH-PASMCs and in GPR75-expressing HEK-293 cells and to effect DNA synthesis in the latter cells. The N-terminal directed GPR75 mAbs increased cAMP accumulation in PAH-PASMCs (
GPR75 has multiple glycosylation sites. Glycosylation can influence the activity of a receptor and hence could contribute to PAH. GPR75 has 3 putative N-glycosylation sites (at position 2, 12, and 25). Results here with PNGase F strongly suggest that GPR75 is glycosylated (
Cellular microparticles (MPs), a heterogeneous population of vesicles with a diameter of 100-1000 nm, are derived from membrane shedding. MPs vary in size, composition and function. Increased circulating MPs occur in PAH patients compared to controls (
In summary, GPCR arrays are useful for profiling cellular GPCR expression and discovering GPCRs that regulate PASMCs and can contribute to the pathophysiology of PAH. Profiling GPCRs in PAH patients may aid in the development of personalized medicine strategies by revealing GPCRs uniquely expressed in IPAH compared to SPAH (Tables 14 and 15). A second personalized medicine approach involves assessment of circulating microparticles (
Having described various embodiments of the invention above, it will be apparent to those skilled in the art that modifications and variations are possible without departing from the scope of the disclosure as defined in the appended claims.
Various publications, including patents, published applications, technical articles and scholarly articles are cited throughout the specification. Each of these cited publications is incorporated by reference herein, in its entirety.
This patent application is a claims priority benefit of U.S. Provisional Application No. 61/860,503 filed on Jul. 31, 2013, which is incorporated herein by reference in its entirety.
This invention was made with Government support under Grant No. HL091061 awarded by the National Institutes of Health. The Government has certain rights in the invention.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2014/049147 | 7/31/2014 | WO | 00 |
| Number | Date | Country | |
|---|---|---|---|
| 61860503 | Jul 2013 | US |
